ORAPRED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAPRED (ORAPRED).
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune responses, and adrenal function.
| Metabolism | Primarily hepatic via CYP3A4; also undergoes reversible metabolism to inactive metabolites. |
| Excretion | Renal: approximately 60-80% as unchanged drug and conjugated metabolites; biliary/fecal: minor (5-10%) |
| Half-life | 4-5 hours (terminal); prolonged in renal impairment (up to 12+ hours in anuria) and hepatic dysfunction; clinical context: dosing interval adjustment in severe renal failure |
| Protein binding | Approximately 70-90%, primarily to albumin and corticosteroid-binding globulin (CBG) |
| Volume of Distribution | 0.8-1.2 L/kg; indicates extensive tissue distribution, including CNS penetration |
| Bioavailability | Oral: 60-90% (dependent on formulation, food reduces rate but not extent) |
| Onset of Action | Oral: 1-2 hours; IV: immediate (within minutes) for immunosuppression |
| Duration of Action | 12-24 hours; clinical note: dose-dependent, with higher doses extending lympholytic effect to 24-36 hours |
| Molecular Weight | 360.44 |
| Action Class | Glucocorticoids |
| Brand Substitutes | Predace 4 Tablet, Coelone 4mg Tablet, Pilsone 4mg Tablet, Premisol 4mg Tablet, Cortilog 4mg Tablet, Rednisol 8 Tablet, Prelid 8mg Tablet, Predace 8mg Tablet, Sterio 8 Tablet, MP 8mg Tablet, Prelid 16mg Tablet, Predace 16 Tablet, Mepresso T 16mg Tablet, Medrol 16mg Tablet, Rednisol 16mg Tablet |
5-60 mg orally once daily or divided as 5-15 mg every 4-12 hours; adjust based on response and condition.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, reduce dose by 50%; for GFR <10 mL/min, reduce dose by 75%. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%. |
| Pediatric use | 0.14-2 mg/kg/day orally in 3-4 divided doses; maximum 60 mg/day. |
| Geriatric use | Initiate at lowest effective dose; consider reduced starting dose (e.g., 2.5-5 mg/day) and monitor for increased sensitivity and adverse effects. |
| 1st trimester | Caution; associated with cleft palate in animal studies; limited human data suggest possible increased risk of orofacial clefts (odds ratio 1.5-3) when used in first trimester. |
| 2nd trimester | Monitor for intrauterine growth restriction; maternal corticosteroid use can cause fetal adrenal suppression, though rare. |
| 3rd trimester | Risk of neonatal adrenal suppression if used near term; may contribute to preterm prelabor rupture of membranes or low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for ORAPRED (ORAPRED).
| Placental transfer | Prednisolone crosses the placenta but is approximately 90% inactivated by 11β-hydroxysteroid dehydrogenase type 2. Degree of fetal exposure depends on maternal dose and gestational age. |
| Breastfeeding | Prednisolone (active metabolite) is excreted into breast milk in low concentrations (<0.1% maternal doses achievable). While generally considered compatible, high maternal doses (>20 mg/day) may warrant monitoring for infant growth and adrenal suppression. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to prednisolone or any excipientSystemic fungal infectionsAdministration of live or live-attenuated vaccines concurrent with immunosuppressive doses
| Precautions | Immunosuppression and increased susceptibility to infections, Adrenal suppression with prolonged use, Osteoporosis risk with long-term therapy, Gastrointestinal perforation risk, Cushing's syndrome with high doses, Psychiatric disturbances, Growth suppression in children, Increased intraocular pressure and glaucoma, Fluid and electrolyte disturbances, Thrombotic events |
| Food/Dietary | Take with food or milk to minimize gastrointestinal irritation. Grapefruit juice may increase prednisolone levels; avoid concurrent consumption. Limit high-sodium foods to reduce fluid retention. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Orapred (prednisolone sodium phosphate) crosses the placenta and is metabolized to prednisolone. First trimester exposure may increase risk of oral clefts (odds ratio 3-5 per 1000 births). Second/third trimester: risk of fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Chronic high-dose use associated with oligohydramnios and premature rupture of membranes. |
| Fetal Monitoring | Maternal: blood pressure, blood glucose, serum electrolytes, adrenal function (if prolonged use), bone density (chronic use). Fetal: growth ultrasound every 4-6 weeks in second/third trimester; amniotic fluid volume assessment; fetal heart rate monitoring if IUGR or oligohydramnios. Neonatal: monitor for signs of adrenal insufficiency (hypoglycemia, hypotension, failure to thrive) for 48-72 hours after delivery. |
| Fertility Effects | No direct evidence of impaired fertility in humans. High-dose corticosteroids may suppress gonadotropin release leading to menstrual irregularities or anovulation, reversible upon dose reduction or discontinuation. No known effects on spermatogenesis. |
| Clinical Pearls | ORAPRED (prednisolone sodium phosphate) is a corticosteroid with high oral bioavailability. Administer with food to reduce GI irritation. Taper dose upon discontinuation to prevent adrenal insufficiency. Monitor for hyperglycemia, especially in diabetic patients. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly. · Take with food or milk to decrease stomach upset. · Avoid live vaccines during treatment. · Report any signs of infection (fever, sore throat) promptly. · Notify healthcare provider if you have diabetes, as blood sugar may increase. · Do not take NSAIDs (e.g., ibuprofen) without consulting your doctor. |